Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for NCNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 0.0685M
March 31, 2026 -0.0094M
December 31, 2025 -0.0916M
September 30, 2025 20.56M
June 30, 2025 12.05M
March 31, 2025 0.5566M
December 31, 2024 2.952M
September 30, 2024 5.936M
June 30, 2024 -0.0854M
March 31, 2024 1.757M
December 31, 2023 -0.053M
September 30, 2023 0.079M
June 30, 2023 -0.0417M
March 31, 2023 -0.0498M
December 31, 2022 0.0398M
September 30, 2022 -0.0455M
June 30, 2022 -0.0918M
Date Value
March 31, 2022 -0.0992M
December 31, 2021 -0.1012M
September 30, 2021 -0.103M
June 30, 2021 -0.1014M
March 31, 2021 0.171M
December 31, 2020 1.436M
September 30, 2020 75.50M
June 30, 2020 2.352M
March 31, 2020 -0.0933M
December 31, 2019 -0.0222M
September 30, 2019 -0.0254M
June 30, 2019 -0.0039M
March 31, 2019 -0.0078M
December 31, 2018 0.0326M
September 30, 2018 0.2453M
June 30, 2018 0.00
March 31, 2018 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Biodexa Pharmaceuticals Plc --
Mereo BioPharma Group Plc 0.00
BioNTech SE -126.88M
Silence Therapeutics Plc 0.002M
Autolus Therapeutics Plc -2.144M